drugset
Drugs / TRASTUZUMAB ENVEDOTIN
last change 9 days ago re-read 2 minutes ago

TRASTUZUMAB ENVEDOTIN

also known as DP303c · Trastuzumab envedotina · Trastuzumab envedotine

Monoclonal antibody targets ERBB2

Developed for
HER2 positive breast carcinoma · cancer · gastric cancer · gastroesophageal adenocarcinoma · neoplasm · ovarian cancer
Investigated by
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Shanghai Runshi Pharmaceutical Technology Co., Ltd

Trials 9 · a red edge is where a trial was stopped

today NCT07241936 · Ph 1/2 NCT06577376 · Ph 1/2 NCT06313086 · Ph 3 NCT05901935 · Ph 3 NCT05810103 · Ph 1 NCT05334810 · Ph 2 NCT04826107 · Ph 2 NCT04828616 · Ph 2 NCT04146610 · Ph 1
202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT05810103 Apr → Dec 2023 HER2 positive breast carcinoma CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04146610 Nov 2019 → Jun 2021 neoplasm CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Unknown No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT07241936 Nov 2025 → Oct 2027 expected cancer CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT06577376 Aug 2024 → Aug 2026 overdue gastroesophageal adenocarcinoma Shanghai Runshi Pharmaceutical Technology Co., Ltd Not yet recruiting No outcome recorded
Phase 23 trials
Phase 2 NCT05334810 May 2022 → Dec 2023 HER2 positive breast carcinoma CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Unknown No outcome recorded
Phase 2 NCT04826107 Aug 2021 → Aug 2024 gastric cancer CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Unknown No outcome recorded
Phase 2 NCT04828616 Jul 2021 → Jul 2023 ovarian cancer CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Unknown No outcome recorded
Phase 32 trials
Phase 3 NCT06313086 Mar 2024 → Dec 2025 overdue HER2 positive breast carcinoma CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT05901935 Jul 2023 → Jan 2026 overdue HER2 positive breast carcinoma CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as TRASTUZUMAB ENVEDOTIN ChEMBL registry synonym — accepted as the source's own label CHEMBL6068184 ↗
Known as DP303c “First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors.” PMID 39266619 ↗ Sep 2024
8

NCT06313086 ↗

NCT06577376 ↗

NCT07241936 ↗

NCT05901935 ↗

NCT05334810 ↗

NCT04828616 ↗

NCT04826107 ↗

NCT05810103 ↗
Known as Trastuzumab envedotina ChEMBL registry synonym — accepted as the source's own label CHEMBL6068184 ↗
Known as Trastuzumab envedotine ChEMBL registry synonym — accepted as the source's own label CHEMBL6068184 ↗
Modality Monoclonal antibody “one anti-HER2 monoclonal antibody” NCT06577376 ↗
Route Intravenous “DP303c was administered intravenously every 3 weeks” PMID 39266619 ↗ Sep 2024
Target ERBB2 “DP303c is a HER2-targeted ADC with a cleavable linker-MMAE payload.” PMID 39266619 ↗ Sep 2024